You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
McKinsey
Johnson and Johnson
McKesson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,300,332

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,300,332
Title: Methods for reducing respiratory depression and attendant side effects of mu opioid compounds
Abstract:A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound.
Inventor(s): Chang; Kwen-Jen (Chapel Hill, NC), McNutt, Jr.; Robert W. (Durham, NC), Pettit; Hugh O. (Cary, NC), Bishop; Michael J. (Durham, NC)
Assignee: Delta Pharmaceuticals, Inc. (Durham, NC)
Application Number:09/352,308
Patent Claims:1. A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, and/or nausea/vomiting as an unwanted side effect in a subject in need thereof, incident to the administration to said subject of a drug mediating said unwanted side effect, said method comprising administering to the subject receiving said drug an effective amount of a .delta. receptor activating compound.

2. The method according to claim 1, wherein the compound also exhibits .mu. receptor agonist character.

3. The method according to claim 1, wherein the compound is administered with a separate .mu. receptor agonist compound.

4. The method according to claim 1, wherein the compound is selected from the group consisting of:

(-)-4-((.alpha.R)-.alpha.-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hy droxybenzyl)-N,N-diethylbenzamide;

(.+-.)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl )-3-hydroxybenzyl)-N,N-dimethylbenzenesulfonamide;

(+)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3 -hydroxybenzyl)-N,N-dimethylbenzenesulfonamide;

(-)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3 -hydroxybenzyl)-N,N-dimethylbenzenesulfonamide,

deltorphin I;

deltorphin II; and

[D-Pen.sup.2,D-Pen.sup.5 ]-enkephalin.

5. A method of reducing, treating or preventing drug-mediated respiratory depression in an animal in need thereof, comprising administering to the animal an effective amount of a compound of the formula: ##STR14##

wherein:

Ar is a 5- or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consistinig of carbon, nitrogen, oxygen and sulfur, and having on a first carbon atom thereof a substituenut Y and on a second ring carbon thereof a substituent R.sup.1,

Y is selected from the group consisting of:

hydrogen;

halogen;

C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl;

C.sub.1 -C.sub.6 haloalkyl;

C.sub.1 -C.sub.6 alkoxy;

C.sub.3 -C.sub.6 cycloalkoxy;

sulfides of the formula SR.sup.8 where R.sup.8 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, arylalkyl having a C.sub.5 -C.sub.10 aryl moiety and an C.sub.1 -C.sub.6 alkyl moiety, or C.sub.5 -C.sub.10 aryl;

sulfoxides of the formula SOR.sup.8 where R.sup.8 is the same as above; sulfones of the formula SO.sub.2 R.sup.8 where R.sup.8 is the same as above;

nitrile;

C.sub.1 -C.sub.6 acyl;

alkoxycarbonylamino (carbamoyl) of the formula NHCO.sub.2 R.sup.8 where R.sup.8 is the same as above;

carboxylic acid, or an ester, amide, or salt thereof;

aminomethyl of the formula CH.sub.2 NR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 may be the same or different, and may be hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.2 -C.sub.6 hydroxyalkyl, C.sub.2 -C.sub.6 methoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.10 aryl, or R.sup.9 and R.sub.10 together may form a ring of 5 or 6 atoms, the ring atoms selected from the group consistinig of N and C;

carboxamides of the formula CONR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are the same as above, or C.sub.2 -C.sub.30 peptide conjugates thereof; and

sulfonamides of the formula SO.sub.2 NR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are the same as above;

Z is selected from the group consisting of:

hydroxyl, and esters thereof;

hydroxymethyl, and esters thereof; and

amino, and carboxamides and sulfonamides thereof;

G is carbon or nitrogen;

R.sup.1 is hydrogen, halogen, or C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkynyl;

R.sup.2 is hydrogen, halogen, or C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkynyl;

R.sup.3, R.sup.4 and R.sup.5 may be the same or different, and are independently selected from hydrogen and methyl, and wherein at least one of R.sup.3, R.sup.4 or R.sup.5 is not hydrogen, subject to the proviso that the total number of methyl groups does not exceed two, or any two of R.sup.3, R.sup.4 and R.sup.5 together may form a bridge of 1 to 3 carbon atoms;

R.sup.6 is selected fiom the group consistinig of:

hydrogen;

C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl;

C.sub.3 -C.sub.6 cycloalkyl;

arylalkyl havinig C.sub.5 -C.sub.10 aryl and C.sub.1 -C.sub.6 alkyl moieties;

alkoxyalkyl having, C.sub.1 -C.sub.4 alkoxy and C.sub.1 -C.sub.4 alkyl moieties;

C.sub.2 -C.sub.4 cyanoalkyl;

C.sub.2 -C.sub.4 hydroxyalkyl;

aminocarbonylalkyl having a C.sub.1 -C.sub.4 alkyl moiety; and

R.sup.12 COR.sup.13, where R.sup.12 is C.sub.1 -C.sub.4 alkylene, and R.sup.13 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy; and

R.sup.7 is hydrogen or fluorine,

or a pharmaceutically acceptable ester or salt thereof.

6. The method according to claim 5, wherein Ar is a 6-member carbocyclic aromatic (benzene) ring and R.sup.1 is hydrogen.

7. The method according to claim 5, wherein Y is a carboxamide of the formula CONR.sup.9 R.sup.10.

8. The method according to claim 7, wherein R.sup.9 and R.sup.10 together form a ring of five or six atoms, thereby forming a pyrrolidinyl or piperidino ring.

9. The method according to claim 7, wherein R.sup.9 and R.sup.10 are the same or different and are each independently selected from hydrogen, C.sub.1 alkyl and C.sub.2 alkyl.

10. The method according to claim 6, wherein Y is hydrogen.

11. The method according to claim 6, wherein Y is a sulfone of the formula SO.sub.2 R.sup.8, and R.sup.8 is C.sub.1 -C.sub.6 alkyl.

12. The method according to claim 6 wherein G is N, R.sup.7 and R.sup.2 are each hydrogen, and Z is hydroxyl.

13. The method according to claim 6, wherein R.sup.6 selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl and C.sub.2 -C.sub.6 alkynyl.

14. A method accordinig to claim 7, wherein R.sup.6 is selected from the group consisting of hydrogen, methyl, propyl, allyl and butenyl.

15. The method according to claim 12, wherein R.sup.3, R.sup.4 and R.sup.5 are hydrogen or methyl, where the total number of methiyl groups is one or two.

16. The method according to claim 5, wherein R.sup.3 and R.sup.5 are both methyl, and R.sup.4 is hydrogen.

17. A method accordinig to claim 1 wherein the compoulid is selected from the group consisting of:

(-)-4-((.alpha.R)-.alpha.-((2R,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hy droxybenzyl)-N,N-diethyl-benzamide;

(-)-4-((.alpha.R)-.alpha.-((2R,5R)-2,5-dimethyl-4-propyl-1-piperazinyl)-3-h ydroxybenzyl)-N,N-diethyl-benzamide;

4-((.alpha.R)-.alpha.-(2S,5S)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxy benzyl)benzamide;

(.+-.)-3-((.alpha.R*)-.alpha.-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl )-3-hydroxybenzyl)benzamide;

N,N-diethyl-4-((.alpha.R)-3-hydroxy-.alpha.-((2R,5R)-2,5-dimethyl-1-piperaz inyl)benzyl)benzamide;

4-((.alpha.R)-.alpha.-((2S,5S)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydrox ybenzyl)-N-ethyl-N-methyl-benzamide;

3-((.alpha.R)-.alpha.-((2S,5S)-4-allyl-2,5-dimethyl-1-piperazinyl)benzyl)ph enol;

(.+-.)-N,N-diethyl-4-((.alpha.R*)-3-hydoxy-.alpha.-((2R*,5S*)-2,4,5-trimeth yl-1-piperazinyl)benzyl)-benzamide;

(+)-4-((.alpha.S)-.alpha.-((2S,5S)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hy droxybenzyl)-N,N-diethylbenzamide;

3-((.alpha.R)-4-(piperidinocarbonyl)-.alpha.-((2S,5S)-2,4,5-trimethyl-1-pip erazinyl)benzyl)phenol;

3-((.alpha.R)-4-(1-pyrrolidinylcarbonyl)-.alpha.-((2S,5S)-2,4,5-trimethyl-1 -piperazinyl)benzyl)phenol;

(.+-.)-3-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl )-4-(methylsulfonyl)benzyl)phenol;

(.+-.)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl )-3-hydroxybenzyl)-N,N-dimethylbenzenesulfonamide;

(+)-4-((.alpha.R)-.alpha.-((2R,5S )-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-dimethylbenzene sulfon-amide; or

(-)-4-((.alpha.R)-.alpha.-((2R,5S)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hy droxybenzyl)-N,N-dimethylbenzenesulfonamide,

(.+-.)-3-((.alpha.R*)-.alpha.-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl )benzyl)phenol;

(.+-.)-4-((.alpha.R*)-.alpha.-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl )-3-hydroxbenzyl)benzamide;

(.+-.)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-2,5-dimethyl-1-piperazinyl)-3-hydr oxybenzyl)-N,N-diethylbenzamide;

(.+-.)-cis-4-(.alpha.-(4-allyl-3,5-dimethyl-1-piperazinyl)-3-hydoxybenzyl)- N,N-diethyl-benzamide;

cis-4-(.alpha.-(3,5-dimethyl-4-(methylallyl)-1-piperazinyl)-3-hydroxybenzyl )-N,N-diethyl-benzamide;

and pharmaceutically acceptable salts thereof.

18. The method accordinig to claim 17, wherein the compound is (-)-4-((.alpha.R)-.alpha.-((2R,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-h ydroxybenzyl)-N,N-diethylbenzamide or a pharmaceutical-ly acceptable salt thereof.

19. A method of treating a patient in need thereof with an opioid receptor therapeutic agent, while attenuating respiratory depression incident to the administration thereof, comprising administering to the patient with said opioid receptor therapeutic agent, a delta agonist compound selected fiom tile group consistilng of:

I. [D-Pen.sup.2,D-Pen.sup.5 ]-(enkephalin);

II. deltorphiln I;

III. deltorphiln II;

IV. .delta. agonist compounds of the formula: ##STR15##

wherein:

Ar is a 5- or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consistinig of carbon, nitrogen, oxygen and sulfur, and having on a first carbon atom thereof a substituent Y and on a second ring carbon thereof a substituent R.sup.1 ;

Y is selected from the group consisting of:

hyrogen;

halogen;

C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl;

C.sub.1 -C.sub.6 haloalkyl;

C.sub.1 -C.sub.6 alkoxy;

C.sub.3 -C.sub.6 cycloalkoxy;

sulfides of the formula SR.sup.8 where R.sup.8 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, arylalkyl having a C.sub.5 -C.sub.10 aryl moiety and an C.sub.1 -C.sub.6 alkyl moiety, or C.sub.5 -C.sub.10 aryl;

sulfoxides of the formula SOR.sup.8 where R.sup.8 is the same as above;

sulfones of the formula SO.sub.2 R.sup.8 where R.sup.8 is the same as above;

nitrile;

C.sub.1 -C.sub.6 acyl;

alkoxycarbonylamino (carbamoyl) of the formula NHCO.sub.2 R.sup.8 where R.sup.8 is the same as above;

carboxylic acid, or an ester, amide, or salt thereof;

aminiomethiyl of the formula CH.sub.2 NR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 may be the same or different, and may be hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.2 -C.sub.6 hiydroxyalkyl, C.sub.2 -C.sub.6 methoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.10 aryl, or R.sup.9 and R.sup.10 together may form a ring of 5 or 6 atoms, the ring atoms selected from the group consistinig of N and C;

carboxamides of the formula CONR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are the same as above, or C.sub.2 -C.sub.30 peptide conjugates thereof; and

sulfonamides of the formula SO.sub.2 NR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are the same as above;

Z is selected from the group consisting of:

hydroxyl, and esters thereof;

hydroxymethyl, and esters thereof; and

amino, and carboxamides and sulfonamides thereof;

G is carbon or nitrogen;

R.sup.1 is hydrogen, halogen, or C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkynyl;

R.sup.2 is hydrogen, halogen, or C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkynyl;

R.sup.3, R.sup.4 and R.sup.5 may be the same or different, and are independently selected from hydrogen and methyl, and wherein at least one of R.sup.3, R.sup.4 or R.sup.5 is not hydrogen, subject to the proviso that the total number of metlhyl groups does not exceed two, or any two of R.sup.3, R.sup.4 and R.sup.5 together may form a bridge of 1 to 3 carbon atoms;

R.sup.6 is selected from the group consisting of:

hydrogen;

C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl;

C.sub.3 -C.sub.6 cycloalkyl;

arylalkyl having C.sub.5 -C.sub.10 aryl and C.sub.1 -C.sub.6 alkyl moieties;

alkoxyalkyl hiaving C.sub.1 -C.sub.4 alkoxy and C.sub.1 -C.sub.4 alkyl moieties;

C.sub.2 -C.sub.4 cyanoalkyl;

C.sub.2 -C.sub.4 hydroxyalkyl;

aminocarbonylalkyl having a C.sub.1 -C.sub.4 alkyl moiety; and

R.sup.12 COR.sup.13, where R.sup.12 is C.sub.1 -C.sub.4 alkylene, and R.sup.13 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy; and

R.sup.7 is hydrogen or fluorine,

or a pharmaceutically acceptable ester or salt thereof;

V. delta agonist compoulids of the formula: ##STR16##

in which,

R.sub.1 and R.sub.2, which can be the same or different, are each hydrogen, linear or branched C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkenyl, C.sub.4-6 cycloalkylalkyl, C.sub.3-6 alkenyl, C.sub.3-5 alkynyl, aryl, aralkyl or furan-2 or 3-yl alkyl or may form together a C.sub.3-7 alkyl ring which may be interrupted by oxygen,

R.sub.3 and R.sub.4, which can be the same or different, are each hydrogen, linear or branched C.sub.1-6 alkyl, or R.sub.4 is oxygen forming with the carbon atom to which is attached a C.dbd.O group;

R.sub.5 is hydrogen, hydroxy, C.sub.1-3 alkoxy, thiol or alkylthio,

R.sub.6 is phenyl, halogen, NH.sub.2 or a para or meta --C(Z)--R.sub.8 group, in which Z is oxygen or sulphur;

R.sub.8 is C.sub.1-8 -alkyl, C.sub.1-8 -alkoxy or NR.sub.9 R.sub.10, wherein R.sub.9 and R.sub.10, which may be the same or different, are hydrogen, straight or branched C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-6 cycloalkylalkyl, C.sub.3-6 alkenyl, aryl or aralkyl,

or R.sub.6 is a para or metal --N--C(Z)--R.sub.12 ##STR17##

in which R.sub.11 and R.sub.12 which nay the same or different are hydrogen, straighit or branched C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-6 cycloalkylalkyl, C.sub.3-6 alkenyl, aryl, aralkyl or an optionally substituited heterocyclic ring, and Z is as defined above; and,

R.sub.7 is hydrogen, straight or branched C.sub.1-8 alkyl or halogen; and

VI. delta agonist compoulids of the formula: ##STR18##

in which,

R.sub.1 and R.sub.2, which can be the same or different, are each hydrogen, linear or branched C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkenyl, C.sub.4-6 cycloalkylalkyl, C.sub.3-6 alkenyl, C.sub.3-5 alkynyl, aryl, aralkyl or furan-2 or 3-yl alkyl or may forn together a C.sub.3-7 alkyl ring which may be interrupted by oxygen,

R.sub.3 and R.sub.4, which can be the same or different, are each hydrogen, linear or branched C.sub.1-6 alkyl;

R.sub.5 is hydroxy, C.sub.1-6 alkoxy, thiol or alkylthio;

R.sub.6 is a --C(Z)--Rg group, in which Z is oxygen or sulphur, R.sub.8 is C.sub.1-8 -alkyl, C.sub.1-8 -alkoxy or NR.sub.9 R.sub.10, wherein R.sub.9 and R.sub.10, which may be the same or different, are hydrogen, straight or branched C.sub.1-6 alkyl, C.sub.3-7 cycloallkyl, C.sub.4-6 cycloalkylalkyl, C.sub.3-6 alkenlyl, aryl or aralkyl,

or R.sub.6 is a ##STR19##

group

in which R.sub.11 and R.sub.12 have the same meaning as R.sub.9 and R.sub.10 or together form an optionally substituted heterocyclic rinig and Z is as defined above, and R.sub.7 is hydrogen, straight or branched C.sub.1-8 alkyl or halogen.

20. A method of reducing, treating or preventinig drug-mediated respiratory depression in an animal in need thereof, incident to the administration to said animal of a respiratory depression-mediatling drug, comprisinig administering to the animal receiving said drug an effective amount of a compound selected from the group consisting of:

(.+-.)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl )-3-hydroxybenzyl)-N,N-dimethylbenzenesulfonamide;

(+)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3 -hydroxybenzyl)-N,N-dimethylbenzenesulfon-amide; and

(-)-4-((.alpha.R*)-.alpha.-((2R*,5S*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3 -hydroxybenzyl)-N,N-dimethylbenzenesulfonamide, and

pharmaceutically acceptable salts thereof.

21. A method of reducing, treatinig or preventinig drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal in need thereof, incident to the administration to said animal of a respiratory depressioni-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist or a mixed delta/mu opioid agonist composition.

22. The method according to claim 21 wherein tlhe respiratory depression mediating drug comprises at least one active ingredient selected from the group consisting of barbiturates, benizodiazepines, opiates, and opioids.

23. The method accordingy to claim 21 wherein the respiratory depression mediatinig drug comprises at least one active ingredient which is an opioid or an opiate.

24. The method according to claim 22 wherein the active ingredient comprises at least one opioid and the opioid comprises a .mu.-receptor aoonist or a mixed .delta./.mu. receptor agonist.

25. Thle method according to claim 21 wherein the respiratory depression mediating drug contains at least one active ingredient selected from the group consisting of alcohol, aldesleukin, alfentanil, bremazocine, buprenorphine, butorphanol, chloropromazine, clozapine, codeine, dantrolene, diazepain, dihydrocodeine, etorphine, fentanyl, flurazepam, heroin, hydrocodone, hydromophone, ketamine, larazepam, levallorphen, levorphanol, meperidine, methadone, methohexital, mitoimycin, morphine, nalbuphine, opium, oxazepam, oxycodone, oxymorplone, pentazocine, phe nobarbital, porfimer, propoxyphene, resperidone, sufenitanil, temazepam, thiopenital, thiorzadine, tramadol, trimethaphan, and zolpidem.

Details for Patent 6,300,332

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Delta Pharmaceuticals, Inc. (Durham, NC) 2012-02-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.